Skip to main content
. 2024 May 15;8(13):3468–3477. doi: 10.1182/bloodadvances.2024012880

Figure 1.

Figure 1.

Overall survival of patients diagnosed with accelerated/blast-phase myeloproliferative neoplasms from 2017 onward. (A) OS of patients diagnosed with MPN-AP/BP from 2017 onward. (B) OS of patients with MPN-AP/BP by frontline treatment approach.